2026-525480-41-00

Trial ID: T-ctis-2026-525480-41-00
Registry: EU Clinical Trials Information System
NCT number: NCT07759245
CTIS number: 2026-525480-41-00
Asset: brenipatide (LY3537031)
Sponsor, as registered: Eli Lilly & Co.
Phase: Therapeutic exploratory (Phase II)
Indication: Pulmonary Disease, Chronic Obstructive
Status: Authorised
Start date: 17/09/2026
Primary completion: CTIS does not publish one.
Member states concerned: Austria, Czechia, Germany, Denmark, France, Hungary, Poland, Romania
Sites: 48

Member states whose regulator has a decision on this trial.

euclinicaltrials.euctis registryverified 2026-09-28

Notes on the record

countries is memberStatesConcerned, i.e. every member state the trial is filed in; site_count sums trialSites across authorised Part II sections. primary_completion_date is EMPTY because CTIS does not publish a primary completion date; it is not unknown, it is not a field the registry has. Per-state authorisation is NOT recorded here; see data/decisions.csv. J2S-MC-GZMV: Phase 2, multicentre, randomised, double-blind, 52-week, brenipatide vs placebo in moderate-to-severe COPD, 265 planned in the EU. Member state decisions: CZ 2026-09-15 authorized 4 sites; DK 2026-09-15 authorized_conditions 7 sites; DE 2026-09-16 authorized 7 sites; FR 2026-09-16 authorized 11 sites; PL 2026-09-16 authorized 3 sites; HU 2026-09-17 authorized 5 sites; AT 2026-09-18 authorized 3 sites; RO 2026-09-18 authorized 8 sites. Overall decision date 2026-09-15, start of trial in the EU 2026-09-17, first published 2026-09-26. Eighth brenipatide CTIS record on the registry (seventh in Phase 2 or 3; a Phase I hepatic-impairment record, 2025-521947-19-00, is not on this file), outside the five the Issue 12 call names. Note corrected 2026-09-28 per issues/issue-16-claims.md item 8; every other field unchanged. Companion ClinicalTrials.gov record NCT07759245 added the same session. Read 2026-09-28.

Company

Through brenipatide (LY3537031): Lilly

Cited in

No published issue cites this registry number.